Literature DB >> 2104806

Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression.

M C Edelstein1, R G Brzyski, G S Jones, S Simonetti, S J Muasher.   

Abstract

This study compares the use of human menopausal gonadotropin (hMG) versus follicle-stimulating hormone (FSH), after gonadotropin-releasing hormone agonist (GnRH-a) suppression for in vitro fertilization. Thirty-seven patients were randomized to ovarian stimulation with either hMG or pure FSH. The GnRH-a leuprolide acetate was administered to all patients beginning in the midluteal phase of the prior cycle and continuing until the day of human chorionic gonadotropin (hCG) administration. There were no significant differences between hMG and FSH cycles with regard to the day of hCG administration, mean peak estradiol levels, number of ampules of medication used, and number of oocytes aspirated, embryos transferred, or pregnancies. We conclude that there is no significant difference between hMG and FSH stimulation when used in conjunction with GnRH-a.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2104806     DOI: 10.1016/s0015-0282(16)53224-5

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  4 in total

1.  Preliminary data on the efficacy of a new human menopausal gonadotropin (hMG) preparation containing a reduced amount of luteinizing hormone (LH) for superovulation in an in vitro fertilization (IVF) program.

Authors:  J M Antoine; J Salat-Baroux; S Alvarez; D Cornet; C Tibi; V Brieu; J Mandelbaum; M Plachot
Journal:  J Assist Reprod Genet       Date:  1992-08       Impact factor: 3.412

2.  A randomized prospective cross-over study of highly purified follicle-stimulating hormone and human menopausal gonadotrophin for ovarian hyperstimulation in women aged 37-41 years.

Authors:  S Bassil; C Wyns; J Donnez
Journal:  J Assist Reprod Genet       Date:  2000-02       Impact factor: 3.412

3.  What is the best protocol for ovarian superovulation?

Authors:  B Hedon; B Camier; F Arnal; C Humeau
Journal:  J Assist Reprod Genet       Date:  1993-10       Impact factor: 3.412

4.  Significance of an abnormal response during pituitary desensitization in an in vitro fertilization and embryo transfer program.

Authors:  S K Goswami; B N Chakravarty; S N Kabir
Journal:  J Assist Reprod Genet       Date:  1996-05       Impact factor: 3.412

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.